medigraphic.com

2025, Number 3

<< Back Next >>

Enf Infec Microbiol 2025; 45 (3)

Antibiotic prescription pattern according to AWaRe classification in a tertiary hospital in Mexico

Torres-Erazo DS, Arcos-Díaz A, Argáez-Ojeda KA, Marín-Alvarado CP

Language: Spanish
References: 24
Page: 133-140
PDF size: 328.23 Kb.


ABSTRACT

Background. WHO developed a classification called AWaRe that allows optimizing the efforts for control and responsible use of antibiotics. According to this classification, this work aimed to determine the prescription pattern of antibiotics in hospitalized patients at the Regional Hospital of High Specialty of the Yucatan Peninsula.
Materials and methods. A descriptive, cross-sectional study lasting 24 weeks, in which prescriptions from hospital were reviewed to identify the characteristics of the prescription. Antibiotics were categorized according to WHO AWaRe classification (access, watch, reserve).
Results. The distribution of antibiotic prescriptions was: 21.3% for access, 74.4% for watch, and 1.4% for reserve; the most commonly prescribed antibiotics for the watch group were ceftriaxone 36.3% and ertapenem 10.6%. More watch type antibiotics were prescribed in surgical services (52.9%) than in clinical services (25.3%). Around 50.6% of the antimicrobials were empirically indicated. In more than half of these prescriptions, a culture was not requested before starting the antibiotic and nor were biological markers used to suspend or de-escalate antibiotic therapy.
Conclusions. A greater antibiotic prescription was observed in the watch category with minimum consumption of reserve antibiotics. It is necessary to reinforce the importance of using tools such as cultures and biological markers for therapeutic decision-making. The aware classification remains a crucial instrument for implementing and evaluating proa in hospitals.


REFERENCES

  1. Truong, W.R. y Yamaki, J., “The hospital antimicrobialuse process: from beginning to end”, Open Forum InfectDis, 2018, 5 (6): ofy098. doi: 10.1093/ofid/ofy098.

  2. Antimicrobial Resistance Collaborators, “Global burdenof bacterial antimicrobial resistance in 2019: a systematicanalysis”, Lancet, 2022, 399 (10325): 629-655. doi:10.1016/S0140-6736(21)02724-0.

  3. World Health Organization, “glass guide for nationalsurveillance systems for monitoring antimicrobialconsumption in hospitals”, World HealthOrganization, 2020. Disponible en: https://iris.who.int/handle/10665/336182.

  4. Versporten, A., Zarb, P., Caniaux, I., Gros, M.-F., Drapier,N., Miller, M. et al., “Antimicrobial consumption andresistance in adult hospital inpatients in 53 countries:results of an internet-based global point prevalencesurvey”, Lancet Glob Health, 2018, 6 (6): e619-e629.doi:10.1016/S2214-109X(18)30186-4.

  5. Levy Hara, G., Rojas-Cortés, R., Molina León, H.F., DreserMansilla, A., Alfonso Orta, I., Rizo-Amezquita, J.N. etal., “Point prevalence survey of antibiotic use in hospitalsin Latin American countries”, J Antimicrob Chemother,2022, 77 (3): 807-815.

  6. Córdoba, G., “Resistencia antimicrobiana y el rol de atenciónprimaria”, Rev Mex Med Familiar, 2022, 9 (2): 38-40.Disponible en http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2696-12962022000200038&lng=es.

  7. Dreser, A., Wirtz J.V. y Corbett, K., “Uso de antibióticosen México: revisión de problemas y políticas”, SaludPública Mex, 2008, 50: S480-S487.

  8. Diario Oficial de la Federación, 9 de noviembre de 2022.Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5670896&fecha=09/11/2022#gsc.tab=0.

  9. Global Point Prevalence Survey of Antimicrobial Consumptionand Resistance, “Data collection forms Global-pps”, sin modulo hai opcional, 2021. Disponible en:https://www.global-pps.com/es/documents/, accesadoen septiembre de 2021.

  10. Zanichelli, V., Sharland, M., Cappello, B., Moja, L., Getahun,H., Pessoa-Silva, C., Sati, H., Van Weezenbeek,C., Balkhy, H., Simão, M., Gandra, S. y Huttner, B., “Thewho aware (access, watch, reserve) antibiotic book andprevention of antimicrobial resistance”, Bull WorldHealth Organ, 2023, 101 (4): 290-296. doi: 10.2471/BLT.22.288614.

  11. Barlam, T.F., Cosgrove, S.E., Abbo, L.M., MacDougall,C., Schuetz, A.N., Septimus, E.J. et al., “Implementingan antibiotic stewardship program: guidelines by theInfectious Diseases Society of America and the Societyfor Healthcare Epidemiology of America”, Clinical InfectiousDisease, 2016, 62 (10): e51-77.

  12. Sosa-Hérnández, O., Vázquez-Zamora, C., Gutiérrez-Muñoz,V.H., Lugo-Zamudio, G.E. y Cureño-Díaz, M.A.,“Resultados del Programa de Uso Racional de Antimicrobianosen un hospital de México, 2013-2018”, RevPanam Salud Pública, 2020, 44: e45.

  13. Soria-Orozco, M., Padrón-Salas, A., González-Mercado,J.J., Villava-Von der Heyde, N., Valerdi-Contreras, L.,López-Íñiguez, A. et al., “Prevalencia de uso de antimicrobianosentre pacientes hospitalizados en áreas nocríticas en un hospital universitario de México”, SaludPública de México, 2017, 59 (5), 504-505.

  14. Torres-Erazo, D.S., Nuñez Caamal, N.J., Carrillo Basulto,M.B., Cicero Ancona, M. y Cuevas Sosa, L.A.,“escuadron meropenem”, “Impact of an antimicrobialstewardship program on the healthcare-associatedinfections in a third-level hospital in Yucatán, Mexico”,Open Forum Infectious Diseases, 2019, 6 (Suppl 2):S687.

  15. Organización Panamericana de la Salud, “Intervencionespara la optimización del uso de antimicrobianos:guía práctica”, Washington, ops, 2024. Disponible en:https://doi.org/10.37774/9789275327692.

  16. Fridkin, S., Baggs, J., Fagan, R., Magill, S., Pollack, L.A.,Malpiedi, P. et al., “Centers for Disease Control andPrevention (cdc). Vital signs: improving antibiotic useamong hospitalized patients”, Morbidity and MortalityWeekly Report, 2014, 63 (9): 194-200.

  17. Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin,M.J. y Bonomo, R.A., “Infectious Diseases Society ofAmerica 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections”, Clin Infect Dis,2024: ciae403.

  18. Schuetz, P., Beishuizen, A., Broyles, M., Ferrer, R., Gavazzi,G., Gluck, E.H. et al., “Procalcitonin (pct)-guided antibioticstewardship: an international experts consensuson optimized clinical use”, Clin Chem Lab Med, 2019,57 (9): 1308-1318.

  19. De Jong, E., Van Oers, J.A., Beishuizen, A., Vos, P., Vermeijden,W.J., Haas, L.E. et al., “Efficacy and safety ofprocalcitonin guidance in reducing the duration of antibiotictreatment in critically ill patients: a randomised,controlled, open-label trial”, Lancet Infect Dis, 2016, 16(7): 819-827.

  20. Paterson, D.L. y Bonomo, R.A., “Extended-spectrumb-lactamases: a clinical update”, Clin Microbiol Rev,2005, 18: 657-686.

  21. Larramendy, S., Gaultier, A., Fournier, J.-P. et al., “Localcharacteristics associated with higher prevalence ofesbl-producing Escherichia coli in community-acquiredurinary tract infections: an observational, crosssectionalstudy”, J Antimicrob Chemother, 2021, 76: 789-795.

  22. Torres-Erazo, D., Núñez-Caamal, N., Villalobos-Díaz, R.y Durán-Falcón, M., “Características de las infeccionesasociadas con la atención de la salud en un hospital detercer nivel de Yucatán, México”, Med Int Méx, 2020,36 (4): 451-459.

  23. Torres-Erazo, D., Domínguez-Méndez, J, Buenfil Vera,L y Cicero Ancona, M., “Clinical and microbiologicalcharacteristics of patients with health care associatedinfections in a high specialized hospital in Yucatan”, EnfInf Microbiol, 2018, 38 (2): 44-49. Disponible en: http://www.amimc.org.mx/wp-content/uploads/2018/08/EIM2-2018-w.pdf.

  24. Karlowsky, J.A., Hoban, D.J., Hackel, M.A. et al., “Resistanceamong gram-negative eskape pathogens isolatedfrom hospitalized patients with intraabdominal and urinarytract infections in Latin American countries: smart2013-2015”, Brazilian J Infect Dis, 2017, 21: 343-348.




2020     |     www.medigraphic.com